Background and aims: Patients with ulcerative colitis (UC) receiving immunosuppressive drugs are at substantial risk of colectomy. We aimed to assess the risk of post-operative complications of tofacitinib exposure before colectomy in comparison with biologics. Methods: A multicentre, retrospective, observational study was conducted in patients with UC who underwent total colectomy for medically refractory disease, exposed to tofacitinib or a biologic before surgery. Primary outcome was the occurrence of any complication within 30 (early) and 90 (late) days after surgery. Secondary outcomes were the occurrence of infections, sepsis, surgical site complications, venous thromboembolic events (VTE), hospital re-admissions, and redo surgery within the same timepoints. Results: Three hundred and one patients (64 tofacitinib, 162 anti-TNFs, 54 vedolizumab, 21 ustekinumab) were included. No significant differences were reported in any outcome, except for a higher rate of early VTE with anti-TNFs ( P =0.047) and of late VTE with vedolizumab ( P =0.03). In the multivariate analysis, drug class was not associated with a higher risk of any early and late complications. Urgent colectomy increased the risk of any early (odds ratio [OR] 1.92, 95% confidence interval [CI] 1.06-3.48) complications, early hospital re-admission (OR 4.79, 95%CI 1.12-20.58), and early redo surgery (OR 7.49, 95%CI 1.17-47.85). A high steroid dose increased the risk of any early complications (OR 1.96, 95%CI 1.08-3.57), early surgical site complications (OR 2.03, 95%CI 1.01-4.09), and early redo surgery (OR 7.52, 95%CI 1.42-39.82). Laparoscopic surgery decreased the risk of any early complications (OR 0.54, 95%CI 0.29-1.00), early infections (OR 0.39, 95%CI 0.18-0.85), and late hospital re-admissions (OR 0.34, 95%CI 0.12-1.00). Conclusions: Pre-operative tofacitinib treatment demonstrated a post-operative safety profile comparable to biologics in patients with UC undergoing colectomy.
Rates of adverse events in patients with ulcerative colitis undergoing colectomy during treatment with tofacitinib vs biologics: a multicenter observational study / Dragoni, Gabriele; Innocenti, Tommaso; Amiot, Aurelién; Castiglione, Fabiana; Melotti, Laura; Festa, Stefano; Savarino, Edoardo Vincenzo; Truyens, Marie; Argyriou, Konstantinos; Noviello, Daniele; Molnar, Tamas; Bouillon, Vincent; Bezzio, Cristina; Eder, Piotr; Fernandes, Samuel; Kagramanova, Anna; Armuzzi, Alessandro; Oliveira, Raquel; Viola, Anna; Ribaldone, Davide Giuseppe; Drygiannakis, Ioannis; Viganò, Chiara; Calella, Francesca; Gravina, Antonietta Gerarda; Pugliese, Daniela; Chaparro, María; Ellul, Pierre; Vieujean, Sophie; Milla, Monica; Caprioli, Flavio; Annalisa Aratari, Francesca Belli, Inês Botto, Elisabetta Bretto, Anneline Cremer, Arianna Dal Buono, Domenico A Giorgi, Javier P Gisbert, Andreas Kapsoritakis, Ioannis Koutroubakis, Alice Laffusa, Triana Lobaton, Olga Maria Nardone, João Neves, Knyazev Oleg, Raffaele Pellegrino, Gilberto Poggioli, Matteo Rottoli, Simone Saibeni. - In: THE AMERICAN JOURNAL OF GASTROENTEROLOGY. - ISSN 0002-9270. - ELETTRONICO. - epub ahed of print:(2024), pp. 1-27. [10.14309/ajg.0000000000002676]
Rates of adverse events in patients with ulcerative colitis undergoing colectomy during treatment with tofacitinib vs biologics: a multicenter observational study
Gilberto Poggioli;Matteo Rottoli;
2024
Abstract
Background and aims: Patients with ulcerative colitis (UC) receiving immunosuppressive drugs are at substantial risk of colectomy. We aimed to assess the risk of post-operative complications of tofacitinib exposure before colectomy in comparison with biologics. Methods: A multicentre, retrospective, observational study was conducted in patients with UC who underwent total colectomy for medically refractory disease, exposed to tofacitinib or a biologic before surgery. Primary outcome was the occurrence of any complication within 30 (early) and 90 (late) days after surgery. Secondary outcomes were the occurrence of infections, sepsis, surgical site complications, venous thromboembolic events (VTE), hospital re-admissions, and redo surgery within the same timepoints. Results: Three hundred and one patients (64 tofacitinib, 162 anti-TNFs, 54 vedolizumab, 21 ustekinumab) were included. No significant differences were reported in any outcome, except for a higher rate of early VTE with anti-TNFs ( P =0.047) and of late VTE with vedolizumab ( P =0.03). In the multivariate analysis, drug class was not associated with a higher risk of any early and late complications. Urgent colectomy increased the risk of any early (odds ratio [OR] 1.92, 95% confidence interval [CI] 1.06-3.48) complications, early hospital re-admission (OR 4.79, 95%CI 1.12-20.58), and early redo surgery (OR 7.49, 95%CI 1.17-47.85). A high steroid dose increased the risk of any early complications (OR 1.96, 95%CI 1.08-3.57), early surgical site complications (OR 2.03, 95%CI 1.01-4.09), and early redo surgery (OR 7.52, 95%CI 1.42-39.82). Laparoscopic surgery decreased the risk of any early complications (OR 0.54, 95%CI 0.29-1.00), early infections (OR 0.39, 95%CI 0.18-0.85), and late hospital re-admissions (OR 0.34, 95%CI 0.12-1.00). Conclusions: Pre-operative tofacitinib treatment demonstrated a post-operative safety profile comparable to biologics in patients with UC undergoing colectomy.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
